AU764716B2 - Calcilytic compounds - Google Patents

Calcilytic compounds Download PDF

Info

Publication number
AU764716B2
AU764716B2 AU65041/00A AU6504100A AU764716B2 AU 764716 B2 AU764716 B2 AU 764716B2 AU 65041/00 A AU65041/00 A AU 65041/00A AU 6504100 A AU6504100 A AU 6504100A AU 764716 B2 AU764716 B2 AU 764716B2
Authority
AU
Australia
Prior art keywords
hydroxy
dimethyl
cyano
amino
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU65041/00A
Other languages
English (en)
Other versions
AU6504100A (en
Inventor
John Fox
Maxine Gowen
Edward F. Nemeth
George B. Stroup
Larry J. Suva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire NPS Pharmaceuticals Inc
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
NPS Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp, NPS Pharmaceuticals Inc filed Critical SmithKline Beecham Corp
Publication of AU6504100A publication Critical patent/AU6504100A/en
Application granted granted Critical
Publication of AU764716B2 publication Critical patent/AU764716B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU65041/00A 1999-07-31 2000-07-31 Calcilytic compounds Ceased AU764716B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14677899P 1999-07-31 1999-07-31
US60/146778 1999-07-31
PCT/US2000/020834 WO2001008673A1 (en) 1999-07-31 2000-07-31 Calcilytic compounds

Publications (2)

Publication Number Publication Date
AU6504100A AU6504100A (en) 2001-02-19
AU764716B2 true AU764716B2 (en) 2003-08-28

Family

ID=22518969

Family Applications (1)

Application Number Title Priority Date Filing Date
AU65041/00A Ceased AU764716B2 (en) 1999-07-31 2000-07-31 Calcilytic compounds

Country Status (21)

Country Link
EP (1) EP1200076A4 (xx)
JP (1) JP2003505502A (xx)
KR (1) KR20020016928A (xx)
CN (1) CN1367687A (xx)
AU (1) AU764716B2 (xx)
BR (1) BR0012921A (xx)
CA (1) CA2380081A1 (xx)
CO (1) CO5180628A1 (xx)
CZ (1) CZ2002360A3 (xx)
EC (1) ECSP003590A (xx)
HK (1) HK1046238A1 (xx)
HU (1) HUP0202167A3 (xx)
IL (1) IL147875A0 (xx)
MX (1) MXPA02001204A (xx)
NO (1) NO20020466L (xx)
PE (1) PE20010459A1 (xx)
PL (1) PL353318A1 (xx)
TR (1) TR200200278T2 (xx)
UY (1) UY26265A1 (xx)
WO (1) WO2001008673A1 (xx)
ZA (1) ZA200200784B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
MY159417A (en) * 2000-01-24 2017-01-13 Smithkline Beecham Corp Calcilytic compounds
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
UY28089A1 (es) 2002-11-26 2004-06-30 Smithkline Beecham Corp Compuestos calciliticos
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
TW200845956A (en) 2006-12-18 2008-12-01 Smithkline Beecham Corp Calcilytic compounds
WO2013098588A1 (en) * 2011-12-27 2013-07-04 Ubaldo Armato Use of calcilytic drugs as a pharmacological approach to the treatment and prevention of alzheimer's disease, alzheimer's disease-related disorders, and down's syndrome neuropathies
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
CN108420814A (zh) * 2017-02-15 2018-08-21 四川大学 一种nps-2143用于抗菌的新用途
CN116173187B (zh) * 2023-03-14 2024-05-10 哈尔滨医科大学 降钙素在制备防治支架内再狭窄药物中的应用、药物涂层支架及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG99290A1 (en) * 1996-04-09 2003-10-27 Nps Pharma Inc Calcilytic compounds
AR018177A1 (es) * 1998-04-08 2001-10-31 Smithkline Beecham Corp Compuestos calciliticos, una composicion farmaceutica que los comprende y el uso de los mismos para la manufactura de un medicamento.
AR014975A1 (es) * 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento

Also Published As

Publication number Publication date
CO5180628A1 (es) 2002-07-30
BR0012921A (pt) 2002-06-18
HUP0202167A3 (en) 2006-07-28
CN1367687A (zh) 2002-09-04
WO2001008673A1 (en) 2001-02-08
CA2380081A1 (en) 2001-02-08
UY26265A1 (es) 2001-03-16
JP2003505502A (ja) 2003-02-12
ZA200200784B (en) 2003-01-29
EP1200076A4 (en) 2005-02-09
TR200200278T2 (tr) 2002-06-21
PL353318A1 (en) 2003-11-17
CZ2002360A3 (cs) 2002-10-16
KR20020016928A (ko) 2002-03-06
EP1200076A1 (en) 2002-05-02
NO20020466L (no) 2002-03-20
IL147875A0 (en) 2002-08-14
ECSP003590A (es) 2002-02-25
MXPA02001204A (es) 2004-05-21
NO20020466D0 (no) 2002-01-29
PE20010459A1 (es) 2001-06-11
AU6504100A (en) 2001-02-19
HK1046238A1 (zh) 2003-01-03
HUP0202167A2 (en) 2002-10-28

Similar Documents

Publication Publication Date Title
AU764716B2 (en) Calcilytic compounds
Wada et al. NPS R-568 halts or reverses osteitis fibrosa in uremic rats
US6221913B1 (en) Dialkyl ureas as calcitonin mimetics
Nagano Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism
Nemeth Pharmacological regulation of parathyroid hormone secretion
EP1466888A1 (en) Calcium receptor-active arylalkyl amines
CZ115398A3 (cs) Přípravky a způsoby pro léčbu deficitních stavů kostí
EP1070048B1 (en) Calcilytic compounds
JP2008115184A (ja) 無機イオン活性化合物
JPH0840911A (ja) 骨損失を抑制するための併用療法
CA2566746A1 (en) Beta adrenergic drug conjugated to bone targeting moiety for modulating bone mass
Shapiro et al. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta
AU750816B2 (en) Piperazine derivatives for treating bone deficit conditions
US20060035927A1 (en) Calcilytic compounds
OA11566A (en) Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone.
AU2001276923B2 (en) Calcilytic compounds
US6864267B2 (en) Calcilytic compounds
WO1998044925A1 (en) Calcilytic compounds
Salt Strontium Ranelate Treatment and Prevention of Osteoporosis, Bone Resorption Inhibitor, Bone Formation Stimulant
WO2019022662A1 (en) PREVENTING SIDE EFFECTS IN THE TREATMENT OF CANCER AND FIBROSIS
WO2005030746A1 (en) Calcilytic compounds
JP2002069003A (ja) ビタミンｄ誘導体を含有する骨吸収抑制剤
US11298348B2 (en) Combination treatment of sarcoglycanopathies
WO2006042007A2 (en) Chromenone compounds as calcilytics
Gegnas Patent focus on agents for osteoporosis: September 1999-February 2000

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)